Silexion Therapeutics (NASDAQ:SLXN) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Silexion Therapeutics (NASDAQ:SLXN) to a hold rating in a report issued on Tuesday morning,Zacks.com reports.

Several other brokerages have also recently weighed in on SLXN. Wall Street Zen raised shares of Silexion Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Wednesday, October 8th. Finally, Litchfield Hills Research started coverage on Silexion Therapeutics in a research note on Monday. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $75.00.

Silexion Therapeutics Stock Down 1.5%

Shares of NASDAQ SLXN opened at $2.57 on Tuesday. The company has a 50 day simple moving average of $3.04 and a 200 day simple moving average of $6.95. The firm has a market cap of $8.04 million, a PE ratio of -0.23 and a beta of -0.06. Silexion Therapeutics has a 1 year low of $2.13 and a 1 year high of $51.75. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.97 and a quick ratio of 3.97.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Wednesday, November 12th. The company reported ($2.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.52.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.